Nektar Therapeutics (NKTR)
Nektar Therapeutics Statistics
Share Statistics
Nektar Therapeutics has 184.46M shares outstanding. The number of shares has increased by 0.46% in one year.
| Shares Outstanding | 184.46M |
| Shares Change (YoY) | 0.46% |
| Shares Change (QoQ) | 0.21% |
| Owned by Institutions (%) | 67.25% |
| Shares Floating | 177.79M |
| Failed to Deliver (FTD) Shares | 12 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 4.72M, so 2.56% of the outstanding shares have been sold short.
| Short Interest | 4.72M |
| Short % of Shares Out | 2.56% |
| Short % of Float | 2.65% |
| Short Ratio (days to cover) | 3.09 |
Valuation Ratios
The PE ratio is -0.39 and the forward PE ratio is -0.98. Nektar Therapeutics's PEG ratio is 0.01.
| PE Ratio | -0.39 |
| Forward PE | -0.98 |
| PS Ratio | 1.19 |
| Forward PS | 1.1 |
| PB Ratio | 0.82 |
| P/FCF Ratio | -0.55 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Nektar Therapeutics has an Enterprise Value (EV) of 317.59M.
| EV / Earnings | -1.15 |
| EV / Sales | 3.52 |
| EV / EBITDA | -1.31 |
| EV / EBIT | -2.31 |
| EV / FCF | -1.64 |
Financial Position
The company has a current ratio of 6.45, with a Debt / Equity ratio of 0.9.
| Current Ratio | 6.45 |
| Quick Ratio | 6.14 |
| Debt / Equity | 0.9 |
| Total Debt / Capitalization | 47.34 |
| Cash Flow / Debt | -1.64 |
| Interest Coverage | -5.42 |
Financial Efficiency
Return on equity (ROE) is -2.11% and return on capital (ROIC) is -55.2%.
| Return on Equity (ROE) | -2.11% |
| Return on Assets (ROA) | -0.69% |
| Return on Capital (ROIC) | -55.2% |
| Revenue Per Employee | $657,824.82 |
| Profits Per Employee | $-2,015,007.3 |
| Employee Count | 137 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 2.28 |
Taxes
| Income Tax | -200K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -10% in the last 52 weeks. The beta is 0.66, so Nektar Therapeutics's price volatility has been higher than the market average.
| Beta | 0.66 |
| 52-Week Price Change | -10% |
| 50-Day Moving Average | 0.9 |
| 200-Day Moving Average | 1.18 |
| Relative Strength Index (RSI) | 44.96 |
| Average Volume (20 Days) | 2.24M |
Income Statement
In the last 12 months, Nektar Therapeutics had revenue of 90.12M and earned -276.06M in profits. Earnings per share was -1.45.
| Revenue | 90.12M |
| Gross Profit | 53.48M |
| Operating Income | -137.43M |
| Net Income | -276.06M |
| EBITDA | -243.11M |
| EBIT | -137.43M |
| Earnings Per Share (EPS) | -1.45 |
Balance Sheet
The company has 35.28M in cash and 117.78M in debt, giving a net cash position of -82.5M.
| Cash & Cash Equivalents | 35.28M |
| Total Debt | 117.78M |
| Net Cash | -82.5M |
| Retained Earnings | -3.48B |
| Total Assets | 307.97M |
| Working Capital | 218.9M |
Cash Flow
In the last 12 months, operating cash flow was -192.61M and capital expenditures -865K, giving a free cash flow of -193.47M.
| Operating Cash Flow | -192.61M |
| Capital Expenditures | -865K |
| Free Cash Flow | -193.47M |
| FCF Per Share | -1.02 |
Margins
Gross margin is 59.34%, with operating and profit margins of -152.49% and -306.31%.
| Gross Margin | 59.34% |
| Operating Margin | -152.49% |
| Pretax Margin | -306.54% |
| Profit Margin | -306.31% |
| EBITDA Margin | -269.75% |
| EBIT Margin | -152.49% |
| FCF Margin | -214.68% |
Dividends & Yields
NKTR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -179.01% |
| FCF Yield | -130.2% |
Analyst Forecast
The average price target for NKTR is $4, which is 393.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $4 |
| Price Target Difference | 393.8% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Aug 23, 2000. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 23, 2000 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | -16.43 |
| Piotroski F-Score | 2 |